AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer (PaTK01).

Trial Profile

AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer (PaTK01).

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Advantagene
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
    • 24 Feb 2015 Planned End Date changed from 1 May 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top